Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy.
Silversides
Candice K
CK
Toronto Congenital Cardiac Centre for Adults, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Webb
Gary D
GD
Harris
Vivien A
VA
Biggar
Douglas W
DW
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D004452:Echocardiography; D004562:Electrocardiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D020388:Muscular Dystrophy, Duchenne / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D011282:Pregnenediones / Q000494:pharmacology* / Q000627:therapeutic use*; D012189:Retrospective Studies; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; C021988:deflazacort